{
    "organizations": [],
    "uuid": "d56ede1dfbe32b346c88f1c2e58fd9769349e9f6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-reports-q1/brief-zynerba-pharmaceuticals-reports-q1-loss-of-0-91-per-share-idUSFWN1SF0Q6",
    "ord_in_thread": 0,
    "title": "BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Zynerba Pharmaceuticals Inc:\n* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS\n* ZYNERBA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.91\n* ZYNERBA - BELIEVES CASH, CASH EQUIVALENT POSITION OF $52.1 MILLION AS OF MARCH 31, IS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO 2019 Source text: ( bit.ly/2IqdNOw ) Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-08T19:30:00.000+03:00",
    "crawled": "2018-05-09T12:20:15.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "zynerba",
        "pharmaceutical",
        "inc",
        "zynerba",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "operational",
        "highlight",
        "zynerba",
        "pharmaceutical",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "zynerba",
        "belief",
        "cash",
        "cash",
        "equivalent",
        "position",
        "million",
        "march",
        "sufficient",
        "fund",
        "operation",
        "capital",
        "requirement",
        "source",
        "text",
        "company",
        "coverage"
    ]
}